Message to Deb in the Vaccines Business Unit

Thanks for your valuable feedback

 

Nice try and stop projecting your own stupidity buddy. No one wants the Sr Dir Trade Strategy position at GSK so the VBU has to look externally.

 

Heyyyyyy what happened to MH at HQs??? She was with us for a long time and gets whacked right after she goes inside and gets promoted?

 

Seriously rude..mind your own business. If she is gone, there was a reason, and it is none of your business.

 

Dips$& that is the whole point of cafepharma. MH was let go bc of expenses.

 

It's simple.....ex-Merck people in the VBU want more of their own so they'll find any excuse to get rid of those who aren't ex-Merck or who won't kiss their asses. No more Merck!

 

Why on earth did we buy NVD for over $5 billion?

 

Morons for leaders

 

You didn't really. Look at the whole deal. Novartis paid GSK $16B for an oncology division worth only $10B then you turn around and pay them $7B for NVD that is only worth $1B. It was a face saving way for Novartis to get out of the vaccines business. You will digest the business and get rid of the bones in a few years and there will be nothing left but a few new vaccines in your portfolio and some residual IP.

Just look at the thread on this subject over in Novartis' Cafe Pharma.

 

Saving face isn't worth all of the disruption caused by the integration.

 

What's in it for GSK to help NVS with saving face?

 

Nothing, the face saving is for Novartis. Getting $16B for an oncology unit that by all normal business practices is worth $10B and Vaccines for free is.

 

Yeah but watch our stock tumble when we're held accountable by Wall Street to make Menveo/Bexsero profitable to justify the $7B price sham.

 

Everyone, especially WS, knows that we didn't "pay $7B" for Novartis Vaccines. Novartis paid us $16B for our Oncology division that standard valuation techniques says is worth $10B (10 times yearly earnings). In return GSK paid Novartis $7B for Vaccines.

So, net net, we got Vaccines for $1B. And there are almost none of the costs that they are carrying that we need to keep in the medium term. This is a pure product / IP play and any extra costs carried over from the acquisition will be quickly eliminated.

Brilliant move by our leadership.

 

Time will tell

 

Yeah the move might be brilliant as long as there isn't a whistleblower about all of NVD's shady marketing practices.

 

Completely product/IP play. One way to make the Novartis money loser of a division profitable quickly? By the product/IP, retain essential Novartis personnel (less than 20%) and slash everything else. No way we retain all of the resources transferring over.

Agree. Good move for GSK.

 

Thanks for responding to your own post.

 

Thanks for responding to your own post. Wait, I already said that.

 

NVS here hey dumb asses wait till you find out what you actually bought. wanna buy some beachfront property in Iowa too?